<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875587</url>
  </required_header>
  <id_info>
    <org_study_id>Cabergoline/calcium gluconate</org_study_id>
    <nct_id>NCT02875587</nct_id>
  </id_info>
  <brief_title>Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome</brief_title>
  <official_title>Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome. A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aljazeera Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aljazeera Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy of calcium gluconate infusion versus
      cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in patients
      pretreated with GnRH agonist long protocol who are at high risk for OHSS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian hyperstimulation syndrome (OHSS) is a serious complication of assisted reproduction.

      Previous studies revealed that calcium gluconate infusion reduced the risk of OHSS. Other
      studies revealed that cabergoline (potent dopamine receptor agonist on D2 receptors)was
      effective in preventing OHSS.

      The aim of this study is to compare the efficacy of calcium gluconate infusion versus
      cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in patients
      pretreated with GnRH agonist long protocol who are at high risk for OHSS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Moderate or severe ovarian hyperstimulation syndrome</measure>
    <time_frame>Within 4 weeks of HCG adminstration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Who Achieved Ongoing Pregnancy</measure>
    <time_frame>18 weeks after embryo transfer</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>OHSS</condition>
  <arm_group>
    <arm_group_label>Cabergoline group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cabergoline is administered starting on the day of HCG administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium gluconate infusion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium gluconate is administered starting on the day of HCG administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabergoline</intervention_name>
    <description>Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration</description>
    <arm_group_label>Cabergoline group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium gluconate</intervention_name>
    <description>Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.</description>
    <arm_group_label>Calcium gluconate infusion group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are stimulated using the long luteal GnRH agonist protocol and at high
             risk for developing OHSS [have more than 18 follicles (&gt; 11mm) and serum estradiol â‰¥
             3000 pg/ml on the day of HCG administration].

        Exclusion Criteria:

          -  Fibrosis of lung

          -  Swelling or inflammation around the heart or lung

          -  Hypertension

          -  Liver disease

          -  Heart valve disease and allergy to cabergoline or ergot derivatives.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Usama M Fouda, M.D,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Aljazeera( Al Gazeera) hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Usama M Fouda, M.D,PhD</last_name>
    <phone>01095401375</phone>
    <email>umfrfouda@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aljazeera hospital</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Usama M. Fouda, M.D , PhD</last_name>
      <phone>01095401375</phone>
      <phone_ext>+2</phone_ext>
      <email>umfrfouda@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Usama M. Fouda, M.D , PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Gurgan T, Demirol A, Guven S, Benkhalifa M, Girgin B, Li TC. Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome. Fertil Steril. 2011 Jul;96(1):53-7. doi: 10.1016/j.fertnstert.2011.04.094. Epub 2011 May 31.</citation>
    <PMID>21621772</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aljazeera Hospital</investigator_affiliation>
    <investigator_full_name>Prof .Usama M.Fouda</investigator_full_name>
    <investigator_title>M.D, PhD</investigator_title>
  </responsible_party>
  <keyword>OHSS</keyword>
  <keyword>Infertility</keyword>
  <keyword>Cabergoline</keyword>
  <keyword>Calcium gluconate</keyword>
  <keyword>IVF-ET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Cabergoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

